LMDXF — LumiraDx Share News
0.000.00%
Last trade - 00:00- $1.64m
- $378.94m
- $254.48m
Brief: LumiraDx Receives CE Mark For Two Multiplex Tests
Brief: LumiraDx Expands Its Cardiovascular Testing Portfolio
Brief: LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need For Diabetes Screening And Monitoring
Brief: Lumiradx Receives WHO Emergency Use Listing For Sars-Cov-2 AG Test
Brief: LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking
Brief: LumiraDx Reports First Quarter 2022 Results
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:48 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:17 AM
Brief: LumiraDx Reports Fourth Quarter And Full Year 2021 Results
NASDAQ RESUMED AT 09:44 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:31 AM
Brief: LumiraDx Announces Pricing Of $56.5 Million Convertible Notes Offering
Brief: Lumiradx Receives UK MHRA Approval For Sars-Cov-2 RNA STAR Complete
U.S. STOCKS ON THE MOVE-Energy stocks, Walt Disney, U.S. airlines, Brinker International
U.S. STOCKS ON THE MOVE-COVID-19 vaccine makers, Bausch Health, Tesla, BlackRock
U.S. STOCKS ON THE MOVE-Walt Disney, Peloton Interactive, Ford, COVID-19 vaccine stocks
LumiraDx COVID-19 antigen tests detect Omicron variant, shares rise
Brief: Lumiradx Lab Analysis Confirms Its Covid-19 Antigen Test Detects The Omicron Variant
Brief: LumiraDx Has Commenced Shipments In Europe For Its Covid-19 & Flu A/B Microfluidic Antigen Test